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FibrillogenesisThe organic solvent dimethylsulphoxide (DMSO) and 1,1,1,3,3,3-hexaﬂuoro-2-isopropanol (HFIP) have been
widely used as a pre-treating agent of amyloid peptides and as a vehicle for water-insoluble inhibitors. These
solvents are left in many cases as a trace quantity in bulk and membrane environments with treated amyloid
peptides or inhibitors. In the present work, we studied the effects of the two organic solvents on the aggregation
behaviors of human islet amyloid polypeptide (hIAPP) and the performances of an all-D-amino-acid inhibitor D-
NFGAIL in preventing hIAPP ﬁbrillation both in bulk solution and at phospholipid membrane. We showed that
the presence of 1% v/v DMSO or HFIP decreases the rate of ﬁbril formation of hIAPP at the lipidmembrane rather
than accelerates the ﬁbril formation as what happened in bulk solution. We also showed that the presence of 1%
v/v DMSO or HFIP impairs the activity of the inhibitor at the lipidmembrane surface dramatically, while it affects
the efﬁciency of the inhibitor in bulk solution slightly.We found that the inhibitor inserts into the lipidmembrane
more deeply or with more proportion in the presence of the organic solvents than it does in the absence of the
organic solvents, which may hinder the binding of the inhibitor to hIAPP at the lipid membrane. Our results
suggest that the organic solvents should be used with caution in studying membrane-induced ﬁbrillogenesis of
amyloid peptides and in testing amyloid inhibitors undermembrane environments to avoid incorrect evaluation
to the ﬁbrillation process of amyloid peptides and the activity of inhibitors.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
The amyloid deposits of proteins have been associated with many
aging and degenerative diseases including Alzheimer's Disease,
Parkinson's Disease, and Type II Diabetes [1–5]. There have been a large
amount of investigations on the structures of amyloid ﬁbrils, mecha-
nisms of ﬁbril formation as well as inhibitions of amyloidogenesis by in-
hibitors. In these studies, organic solvents, such as dimethylsulphoxide
(DMSO) and 1,1,1,3,3,3-hexaﬂuoro-2-isopropanol (HFIP), have been
widely used to treat synthetic peptides so as to disassociate pre-
existing aggregates. Besides, DMSOhas also beenwidely used as a vehicle
for water insoluble inhibitors [6–11]. Some assays of amyloid peptides
were performed in bulk solutions or in membrane environments by di-
luting a stock solution of amyloid peptides in DMSO or HFIP directly. In
these cases, the organic solvents were left as a trace quantity in bulk or
membrane environments (in most cases the organic solvents were not
more than 2.5% v/v) [12,13]. The presence of a trace quantity of HFIP in
bulk solution has beendemonstrated to accelerate the formation ofﬁbril-
lar aggregates [14].Supramolecular Structure and
un 130012, PR China. Tel.: +86The interactions of DMSOwith lipidmembrane surfaces were inves-
tigated by experimental measurements and molecular dynamics simu-
lations, and a number of features which are signiﬁcant with respect to
the effects of DMSO onmembrane structure and functionwere revealed
[15–21]. DMSO molecules occupy a position just beneath the lipid
headgroups and affect lipid membrane structure by displacing water,
reducing bilayer thickness, increasing headgroup area, inducing
water pore formation, etc. The perturbation of HFIP to phospholipid
membranes was demonstrated to be pronounced. HFIP has a high afﬁn-
ity for liposomal membranes [22]. Even low concentration of HFIP
(0.01%–0.06% v/v) can adversely affect membranes and alter their
permeability for ions [23,24]. Therefore, it can be supposed that the
presence of organic solvent at lipid membranes would change the
micro-environments of both amyloid peptides and inhibitors, interfere
with ﬁbril growth of amyloidogenic peptides at membrane surfaces
and affect the binding of inhibitors to amyloid peptides. Moreover, the
organic solvents, even at a low concentration, also can exert an effect
on the folding of amyloid peptides [14,25–27]. Although a facilitating
role of a trace quantity of HFIP for the amyloid ﬁbrillation in bulk solu-
tion was reported, the effects of organic solvents on the aggregation
behaviors of amyloid peptides at lipidmembranes andmore important-
ly on the inhibitory efﬁciency of amyloidogenic inhibitors at lipid mem-
branes were almost ignored in previous studies. If the solvent effects
really exist, the introduction of the organic solvents in the assays
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amyloid peptide and to the activity of an inhibitor.
In this study, we detected the effects of the organic solvents on the
aggregation behaviors of human islet amyloid polypeptide (hIAPP)
and on the performances of an all-D-amino-acid inhibitor in blocking ﬁ-
bril formation of hIAPP either in bulk solution or at the phospholipid
membrane surface using thioﬂavin-T (ThT) ﬂuorescence spectroscopy,
atomic force microscopy (AFM), transmission electron microscopy
(TEM) and far-ultraviolet circular dichroism (CD).
2. Materials and methods
2.1. Materials
Synthetic hIAPP (1–37) with an amidated C-terminus and an oxi-
dized disulﬁde between Cys2 and Cys7 was obtained from Shanghai
Sci. Pept. Biol. Technol. Co., Ltd (Shanghai, China). The sample purity
was greater than 95%. The short peptide composed of an all-D-amino-
acid, D-NFGAIL, with purity greater than 98% was purchased from
APeptide Co. Ltd (Shanghai, China). The phospholipids 1-palmitoyl-2-
oleoyl-sn-glycero-3-phosphocholine (POPC) and 1-palmitoyl-2-oleoyl-
sn-glycero-3-phospho-(1′-rac-glycerol) (POPG) were purchased from
Avanti Polar Lipids (Alabaster, AL, USA). DMSO (99%), HFIP (99.5%)
and other chemical agents were obtained from Sigma-Aldrich
(St. Louis, MO, USA). The peptides and chemical agents were used as
purchased without further treatment.
2.2. Preparation of solutions
Stock solutions of a certain quantity of hIAPP in DMSO or HFIP were
prepared by solubilizing synthetic hIAPP powder in the organic solvent
and sonicating themixture in water bath for 2min. The DMSO and HFIP
solutions of the all-D-amino-acid inhibitor were prepared similarly be-
fore each experiment. A 25 mM phosphate buffer with 25 mM NaCl at
pH 7.4 was prepared and used for all experiments.
2.3. Small unilamellar lipid vesicles (SUVs)
POPC and POPG with the molar ratio of POPC:POPG 7:3 were dis-
solved in chloroform/methanol (2:1 v/v) and gently dried under a dry
nitrogen ﬂux. The lipid ﬁlm was vacuum-desiccated overnight. The
dry lipid ﬁlm was rehydrated using phosphate buffer and bath-
sonicated for 1 h. The liposomewas used immediately after preparation.
2.4. Thioﬂavin-T ﬂuorescence spectroscopy
The samples of 15 μM hIAPP in bulk solutions containing 1% v/v or-
ganic solvent or the samples of 15 μM hIAPP in liposome solutions con-
taining various quantities of organic solvent (0.05%–1% in v/v) were
prepared. The ThT of 20 μMwas added in all samples. The lipid concen-
tration of 2.25 mM (lipid:hIAPP = 150:1) was used. The samples for
testing the performance of inhibitor were prepared by mixing different
quantities of inhibitor stock solution with a certain quantity of hIAPP
stock solution and then adding buffer or freshly prepared liposome
solution in the mixtures immediately. The time dependence of ﬂuores-
cence intensity was monitored immediately after the sample prepara-
tion using an RF-5301PC spectroﬂuorophotometer (Shimadzu, Japan)
at an emission wavelength of 482 nm and an excitation wavelength of
440 nm. The spectra were recorded at room temperature without shak-
ing. All experiments were repeated at least twice by individually pre-
pared samples to ensure the results reproducible.
2.5. Transmission electron microscopy
The samples of 5 μL used in ThT assays were deposited on a 300-
mesh Formvar-carbon coated copper grid (Shanghai, China) for 2 minat room temperature. Excess samples were removed using ﬁlter paper
followed by washing twice with 10 μL Milli-Q water. Then, the samples
were air-dried overnight and stained with 1% freshly prepared uranyl
formate. The samples were observed under a transmission electron
microscope (JEM-2100F, JEOL Co., Ltd., Japan) operating at an accelerat-
ing voltage of 200 kV.
2.6. Far-ultraviolet circular dichroism
Far-UV CD spectra were measured at room temperature under a
constant ﬂow of nitrogen gas by using a PMS-450 spectropolarimeter
(Biologic, France). A 0.1 mm quartz cuvette was used for all CD spectra.
Data were recorded from 260 to 190 nm with 1 nm sampling interval.
The samples used in CD experiments were prepared similarly to those
used in ThT assays except the addition of ThT dye. The ﬁnal spectra
were the average of three repeated experiments and the background
(the CD spectrum of the sample without hIAPP) was subtracted.
2.7. Atomic force microscopy
AFM was performed as previously described [28]. Brieﬂy, the hIAPP
stock solution was mixed with freshly prepared SUV solution (POPC:
POPG 7:3) at a 25:1 molar ratio of lipid:peptide and at a 1% v/v concen-
tration of HFIP or DMSO. The mixture was incubated at room tempera-
ture for 30 min. The liposome solution of 20 μL was then deposited on
freshly cleaved mica for 20 min and allowed to heat at 65 °C for 5 min
to promote fusion and formation of planar lipid bilayers [29]. All images
were recorded using SPA-300 AFM instrument (Seiko Instruments Inc.,
Japan) in a contact mode.
2.8. Acrylamide ﬂuorescence quenching experiment
The quenching experiments of phenylalanine (Phe) ﬂuorescence
were performed on an RF-5301PC spectroﬂuorophotometer at room
temperature using acrylamide as a quencher. The SUV samples of
15 μM hIAPP and those of 15 μM all-D-amino-acid inhibitor in the
absence and presence of 1% v/v DMSO or HFIP were used, and the
lipid:peptide ratio was ﬁxed at 150:1 in all these experiments. The ﬂuo-
rescencewas excited at 256nmand the emissionwas scanned from270
to 400 nm. Three scans were collected and averaged. The ﬂuorescence
spectrum of liposome alone as the background was subtracted. A series
of ﬂuorescence spectra were measured after serial addition of small
aliquots of freshly prepared acrylamide solution (5 M) into the
peptide-incorporated SUV solution. The relation of the ﬂuorescence in-
tensity with the concentration of the quencher [Q] was determined by
the Stern–Volmer equation [30]:
F0=F ¼ 1 þ Ksv Q½  ð1Þ
where F0 and F are the ﬂuorescence intensity in the absence and pres-
ence of the quencher, respectively, and Ksv is the quenching constant.
3. Results and discussion
3.1. Effects of the organic solvents on hIAPP ﬁbrillation and inhibitor activity
in bulk solution
The ﬁbrillation behaviors of hIAPP in bulk solution were monitored
by the ThT ﬂuorescence assay in the absence and presence of organic
solvents. In the presence of 1% v/v DMSO, the ThT ﬂuorescence
displayed a higher initial intensity and the intensity increased with
time to a plateau in ~1 h. A characteristic lag phase that existed in the
ThT assay of hIAPP in bulk solution without the organic solvent
(~1.5 h) was not observed (Figs. 1A and S1). This suggests that the
early aggregation of hIAPP before the formation of ﬁbrils is promoted
by the presence of 1% v/v DMSO. The TEM image conﬁrmed the
Fig. 1. The ThTmonitored kinetic processes of aggregation of hIAPP alone and hIAPPmixedwith different molar ratios of D-NFGAIL in bulk solution containing 1% v/v DMSO (A), the TEM
images of hIAPP incubated alone (B) and incubated with an equimolar D-NFGAIL (C) in bulk solution containing 1% v/v DMSO for 24 h, and the corresponding results from 1% v/v HFIP
containing solutions (D–F). The scale bars in all images are 500 nm.
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(Fig. 1B). The morphology of the ﬁbrils formed in the presence of 1% v/v
DMSO was similar to that formed in the absence of the solvent [28],
suggesting that the growth pattern of hIAPP ﬁbrils is not signiﬁcantly
affected by the organic solvent.
An all-D-amino-acid inhibitor D-NFGAIL that has been conﬁrmed to
be efﬁcient in preventing the formation of hIAPP ﬁbrils [28] was used to
detect the effects of the organic solvents on the performance of the in-
hibitor. When an equimolar amount of inhibitor was added in the
hIAPP bulk solution with 1% v/v DMSO, the ThT ﬂuorescence intensity
was dramatically decreased (Figs. 1A and S1) and no amyloid ﬁbrils
were detected by the TEM image (Fig. 1C). This indicates that the poten-
cy of the inhibitor in blocking hIAPP ﬁbril formation is almost not affect-
ed by 1% v/v DMSO, or the interaction between the inhibitor and hIAPP
is not signiﬁcantly affected by the organic solvent. Similar results were
also obtained for hIAPP in bulk solution with 1% v/v HFIP (Figs. 1D–F
and S1).3.2. Effects of the organic solvents on hIAPP ﬁbrillation and inhibitor activity
at the phospholipid membrane surface
The ThT ﬂuorescence assay showed that the introduction of 1% v/v
DMSO in the SUV solution postponed the formation of hIAPP ﬁbrils as
the lag phase increased from ~5 min in the absence of DMSO to
~20 min in the presence of 1% v/v DMSO (Figs. 2A and S2). The differ-
ence between the morphologies of hIAPP aggregates in the presence
and in the absence of DMSO was also observed by the AFM image
(Fig. 2B). Besides the linear structure, the peptide also formed the ﬁbrils
of circular structure at the membrane in the presence of DMSO.
With the addition of an equimolar amount of inhibitor D-NFGAIL,
the time dependence of the ThT ﬂuorescence for hIAPP ﬁbrillation at
the lipid membrane treated with 1% v/v DMSO was signiﬁcantly differ-
ent from that in the absence of DMSO. Whereas the increase in the
ThT ﬂuorescence intensity was completely suppressed at the 1:1 ratio
of inhibitor:hIAPP in the absence of DMSO (also see ref. [28]), it was
Fig. 2. The aggregation behaviors of hIAPP at the lipidmembrane surface containing 1% v/vDMSO. (A) The ThTmonitored kinetic processes of aggregation of hIAPP alone and hIAPPmixed
with differentmolar ratios ofD-NFGAIL; (B–D) the AFM images of hIAPP incubatedwith liposome in the absence and presence of inhibitor for 50min: (B) hIAPP alone, (C)D-NFGAIL:hIAPP
1:1, (D) D-NFGAIL:hIAPP 3:1. The ratios of lipid:hIAPP are 150:1 in the ThT assays and 25:1 in the AFM assays. The inserts in the AFM images (B–D) are the parallel results obtained in the
absence of DMSO. The scale bars in all images are 1 μm.
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DMSO (Figs. 2A and S2). The addition of even ten times of inhibitor in
the SUV solution of hIAPP with 1% v/v DMSO only resulted in a smaller
change in the kinetic behavior of hIAPP aggregation, but did not prevent
the increase in the ThT ﬂuorescence intensity. The severe impairing of
DMSO to the efﬁciency of the inhibitor at the lipid membrane was also
conﬁrmed by the AFM images, where abundant ﬁbrils of hIAPP were al-
ways observed at the inhibitor:hIAPP ratios from1:1 to 20:1 in the pres-
ence of 1% v/v DMSO (Fig. 2C and D, also see Fig. S3 for the AFM images
at the inhibitor:hIAPP ratios of 10:1 and20:1). In contrast, the formation
of ﬁbrils was prevented largely by the inhibitor at inhibitor:hIAPP of 1:1
and blocked completely at inhibitor:hIAPP of 3:1 (see the inserts in
Fig. 2C and D, also see ref. [28]). We also measured the AFM images of
the inhibitor alone in the SUV solution with 1% v/v DMSO after the
same incubation time (Fig. S4). No any apparent aggregates were ob-
served on the AFM images, even when the inhibitor concentration
was as high as 300 μM (corresponding to the inhibitor concentration
used in the assay of inhibitor:hIAPP 20:1). This conﬁrmed that the ﬁbrils
appearing in the AFM images resulted from the hIAPP but not the
inhibitor.
The ThT assay of hIAPP at the lipid membrane treated with 1% v/v
HFIP showed a gradual increase in the ﬂuorescence intensity without
an initial delay (Figs. 3A and S2). The intensity reached to the plateau
after ~40 min. In contrast, the ThT ﬂuorescence intensity rose steeply
after a delay of ~5 min and reached to the plateau after ~25 min in
the absence of HFIP (Fig. 3A). This indicates that the early aggregation
of hIAPP is promoted by 1% v/v HIFP at the membrane surface, but the
growth rate of the ﬁbers is reduced at the membrane treated with 1%
v/v HFIP. The presence of 1% v/v HFIP also affected the morphology ofhIAPP ﬁbrils formed at the lipid membrane. Although abundant ﬁbrils
of hIAPP were detected by AFM image after 50 min incubation at the
membrane with 1% v/v HFIP (Fig. 3B), it was noted that the ﬁbrils
formed at the lipid membrane with 1% v/v HFIP seems thicker and
shorter than those formed in the absence of the solvent (the insert in
Fig. 2B).
More importantly, the introduction of 1% v/v HFIP at the lipid mem-
brane impaired the activity of the all-D-amino-acid inhibitor in blocking
the formation of ﬁbrils dramatically. The addition of the inhibitor in the
liposome solution with 1% v/v HFIP only resulted in a dose dependent
extension of the lag phase in the ThT ﬂuorescence spectra (Fig. 3A),
whereas the increase in the ThTﬂuorescence intensity of hIAPP incorpo-
rated with SUVs alone was completely suppressed at the molar ratio of
inhibitor to hIAPP for 1:1. The increase in the ThT ﬂuorescence intensity
of hIAPP at the lipid membrane in the presence of 1% v/v HFIP was not
suppressed even at themolar ratio of inhibitor to hIAPP for 10:1. The ad-
verse effect of HFIP on the inhibitory efﬁciency was clearly observed in
the AFM images of hIAPP reconstructed at the membrane surface treat-
ed with 1% v/v HFIP. Abundant short and straight ﬁbers were observed
at the inhibitor:hIAPP ratios from 1:1 to 10:1 (Figs. 3C, D and S5). The
ﬁbrils appearing in the AFM images were attributed unambiguously to
the amyloid peptides but not the inhibitor, as the inhibitor alone did
not form ﬁbrils in the same conditions (see Fig. S6).
3.3. Effects of the organic solvents on the structure of hIAPP at the lipid
membrane
The effects of DMSO and HFIP on the structure of hIAPP at the mem-
brane surface were analyzed by the CD spectroscopy. Our previous
Fig. 3. The aggregation behaviors of hIAPP at the lipid membrane surface containing 1% v/vHFIP. (A) The ThTmonitored kinetic processes of aggregation for hIAPP alone and hIAPPmixed
with differentmolar ratios ofD-NFGAIL; (B–D) the AFM images of hIAPP incubatedwith liposome in the absence and presence of inhibitor for 50min: (B) hIAPP alone, (C)D-NFGAIL:hIAPP
1:1, (D) D-NFGAIL:hIAPP 3:1. The ratios of lipid:hIAPP are 150:1 in the ThT assays and 25:1 in the AFM assays. The scale bars in all images are 1 μm.
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bation time at the membrane without the organic solvent [28]. The CD
results in the present study showed that the organic solvents have
an effect on the initial structure of hIAPP at the membrane. In the ab-
sence of inhibitor, hIAPP formed either a β-sheet structure at the
membrane with 1% v/v DMSO or an α-helix structure at the membrane
with 1% v/v HFIP at an initial incubation time (Fig. 4). The peptide
formed a β-sheet structure after 45 min incubation under both condi-
tions, which is similar to the case of hIAPP at the membrane without
the organic solvent. In the presence of the inhibitor, the initial structures
of hIAPP at the membrane with 1% v/v DMSO depended on the ratio of
inhibitor:hIAPP, e.g., a β-sheet structure at a 1:1 ratio and an α-helix
structure at a 10:1 ratio, while the initial structures of hIAPP at the
membrane with 1% v/v HFIP were α-helix at all inhibitor:hIAPP ratios
studied. Despite having the different initial structures, hIAPP aggregated
at the membranes containing the organic solvents to form ﬁbrils with a
β-sheet structure after 45min incubation. In contrast, the initialα-helix
structure is stabilized and the conversion from anα-helix to a β-sheet is
blocked by the all-D-amino-acid inhibitor at themembranewithout the
organic solvent [28]. As a result, the ﬁbrillation of hIAPP is inhibited. The
CD results indicate that the potency of the inhibitor in speciﬁc stabiliza-
tion of an α-helix structure or α-helical intermediates of hIAPP at the
membrane surface is abolished by the presence of DMSO and HFIP.
3.4. Effects of the organic solvents on the interactions of either inhibitor or
hIAPP with the lipid membrane
Although the organic solvents impose effects on the structures of
hIAPP monomers or oligomeric intermediates at phospholipid mem-
brane, the structural change may not be a direct cause that leads to
the loss in the activity of the all-D-amino-acid inhibitor. The ﬁbrilformation from either the α-helical intermediates or from the β-sheet
intermediates can be disrupted by the D-peptide in the absence of the
organic solvents [28]. A more direct factor for the invalidation of the in-
hibitor could originate from the obstruction of the inhibitor binding
with hIAPP at the lipid membrane disturbed by the organic solvents.
As we know, the presence of DMSO or HFIP in lipid membrane is able
to change the property of membrane. Thus, the interactions of hIAPP
and inhibitor with the lipid membrane or the insertion of the two pep-
tides in themembrane should be inﬂuenced. In order to examine the ef-
fects of the organic solvents on the insertion of hIAPP and the D-peptide
inhibitor in the membrane, we performed the acrylamide ﬂuorescence
quenching experiments for hIAPP and the inhibitor in liposome solution
separately.
The emission spectra of Phe residue in inhibitor weremonitored at a
serial concentration of acrylamide. As shown in Fig. 5, the introduction
of 1% v/v DMSO or 1% v/v HFIP in the liposome solution of inhibitor led
to an evident increase in the ﬂuorescence intensity before the addition
of acrylamide. With the addition of acrylamide, the ﬂuorescence inten-
sity wasmuchmore quickly quenched in the absence of the organic sol-
vents than it was in the presence of the organic solvents. The Ksv values
(or the slopes of the straight lines in Fig. 5D) obtained in the presence of
the organic solvents were smaller than that obtained in the absence of
the organic solvents by about one order of magnitude. One possibility
to interpret this result is a deeper insertion of the inhibitor in themem-
brane in the presence of 1% v/vDMSO andHFIP. Another possibility is an
increasing portioning of the inhibitor in the membrane. Either deeper
insertion or more portioning in lipid membrane with 1% v/v DMSO or
HFIP is clearly unfavorable for the interaction of the inhibitor with
hIAPP.
Considering the fast aggregation of hIAPP at the lipid membrane, we
performed the quenching experiments of the Phe emission at only one
Fig. 4. The CD spectra of hIAPP alone, hIAPPmixedwith D-NFGAIL at 1:1 and 1:10 ratios incubated at the lipid membrane containing 1% v/v HFIP (A–C) and 1% v/v DMSO (D–F) for 0 and
45 min.
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the sample preparation. The results showed that the introduction of
1% v/vHFIP in the liposome solution of hIAPP has little effect on the ﬂuo-
rescence intensity, while the addition of 1% v/v DMSO causes a decrease
in intensity (Fig. 6). The quenching by acrylamide resulted in a decrease
in the ﬂuorescence intensities with a similar magnitude for the lipo-
some samples of hIAPP either with or without the organic solvents
(the value of F0/F was 2.3 in the absence of organic solvent and the
values were 1.8 and 1.7 in the presence of 1% v/v HFIP and DMSO, re-
spectively), whereas the introduction of the organic solvents induced
larger change in the quenching magnitude for the liposome samples
of the inhibitor at 100mMacrylamide (the F0/F values for the three lipo-
some samples of inhibitor were 9.9, 2 and 1.45). This suggests that the
interaction of inhibitor with lipids was much more impacted by theorganic solvents than the interaction of hIAPPwith lipids. The increasing
embedding or portioning of the inhibitor in the membrane may be a
main and direct factor that leads to the activity losing of the all-D
amino-acid inhibitor in preventing hIAPP ﬁbrillation.
It was noteworthy that the results of the quenching assays for the
hIAPP liposome samples containing 1% v/v organic solvents displayed
the F0/F values somewhat smaller than that of the liposome sample of
hIAPP without the organic solvents. This implies that the presence of
the organic solvents may induce a little deeper embedding of hIAPP in
the membrane. This result can be used to explain why the hIAPP ﬁbril-
lation at the lipid membrane was slowed by the introduction of the or-
ganic solvents. A little deeper insertion of hIAPP in themembrane in the
presence of the organic solvents could decrease the interactions of
hIAPP with themselves, and thus slow the growth rate of ﬁbrils.
Fig. 5. The acrylamideﬂuorescence quenching spectra of the all-D-amino-acid inhibitor in pure liposome solution (A), in the liposome solution containing 1% v/vDMSO(B) and 1% v/vHFIP
(C), as well as the Stern–Volmer plots obtained from the spectral data (D).
Fig. 6. The ﬂuorescence spectra of hIAPP in pure liposome solution (A), in the liposome solution containing 1% v/vDMSO (B) and 1% v/vHFIP (C) before (black) and after (red) the addition
of acrylamide.
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ﬁbrillation and the efﬁciency of the inhibitor at the lipid membrane are not
affected
The ﬁbrillation of hIAPP at the lipid membrane mixed with various
quantities of organic solvents wasmonitored using ThT ﬂuorescence as-
says either in the absence or in the presence of the inhibitor D-NFGAIL
(Figs. 7 and S7). The ThT ﬂuorescence data showed that the changes
in the kinetic processes of the hIAPP ﬁbrillation induced by the organic
solvents were decreased with the decrease in the amount of the sol-
vents at the membrane. The kinetic processes of the hIAPP ﬁbrillation
in the presence of the organic solvents were close to that of the ﬁbrilla-
tion of hIAPP alone when the amount of HFIP was decreased to 0.2% v/v
and the amount of DMSO was decreased to 0.05% v/v. Interestingly, the
activity of the D-peptide inhibitor in preventing the formation of hIAPP
ﬁbrils at the lipid membrane was increased as the concentrations of the
organic solvents were decreased. The ﬂuorescence intensity was fully
suppressed at about 0.2% v/v HFIP, while a small extent of ﬂuorescence
increase was still observed even at 0.05% v/v DMSO. The maximal con-
centrations of the organic solvents obtained in the absence and pres-
ence of the inhibitor were very close, suggesting that the perturbation
of the organic solvents to lipid membrane may play a more important
role in changing the hIAPP ﬁbrillation and the inhibitor performance
than the effects by the interactions of the solvents with the peptides
(hIAPP and inhibitor). In addition, it was clearly showed that the maxi-
mal concentration of DMSO is lower than that of HFIP. This indicates
that DMSO strengthens the interactions of the D-peptide inhibitor and
hIAPP with the lipid membrane more effectively than HFIP does.
The maximal allowed concentrations of organic solvents may differ
in different conditions, depending on such as the property of a peptideFig. 7. The ThT monitored kinetic processes for hIAPP ﬁbrillation at the lipid membrane conta
presence of an equimolar D-peptide inhibitor (C and D).and an inhibitor, the composition of membrane, the concentration of
each component, and the environment or matrix. The mechanism and
extent of the role of organic solvent in disturbing amyloidogenesis and
inhibitor activity may be also different in different cases. Nevertheless,
the effects of organic solvents should be evaluated in the experiments
with respect to amyloid peptides if organic solvents are used, especially
in the experiments involved in liposome.
4. Conclusion
Our results in this study demonstrate that the presence of a trace
amount of organic solvents alters both the kinetics of hIAPP ﬁbrillation
and the binding of inhibitor with the amyloid peptide at the lipidmem-
brane surface considerably. In this case, the ﬁbril growth of hIAPP can-
not be disrupted efﬁciently by the inhibitor. The increasing insertion
depth or proportion of the D-peptide inhibitor in the lipid membrane
embeddedwith organic solventsmay be a key factor for the inefﬁciency
of the inhibitor. This study reveals that the presence of the organic
solvents could introduce deviation in studying the kinetic behaviors of
amyloid peptides and more importantly could lead to an opposite con-
clusion in estimating the efﬁciency of inhibitors of amyloid peptides.
Our results suggest that the organic solvents should be used with cau-
tion in studying membrane-induced ﬁbrillogenesis of amyloid peptides
and in testing amyloid inhibitors under membrane environments to
avoid incorrect evaluation to theﬁbrillation process of amyloid peptides
and the activity of inhibitors.
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